ACR 28: Triple-Negative Breast Cancer Awareness Month.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-05-03
Current Status:
Passed
(2023-05-03: Chaptered by Secretary of State - Res. Chapter 39, Statutes of 2023.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
This measure would proclaim the month of March 2023 as Triple-Negative Breast Cancer Awareness Month.
This measure would proclaim the month of March 2023 as Triple-Negative Breast Cancer Awareness Month.
This measure would proclaim the month of March 2023 as Triple-Negative Breast Cancer Awareness Month.
WHEREAS, Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States; and
WHEREAS, Approximately 297,790 women will be diagnosed with breast cancer and over 43,000 will die with this malignancy in 2023; and
WHEREAS, Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 20 percent of all diagnosed invasive breast cancer cases in the United States; and
WHEREAS, More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer, with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdominal area, and those with breast cancer gene 1 (BRCA1) mutations; and
WHEREAS, Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer, and
WHEREAS, People diagnosed with metastatic triple-negative breast cancer have a less-than-30-percent chance of surviving past five years; and
WHEREAS, Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer; and
WHEREAS, Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians; and
WHEREAS, Recent innovations in targeted therapies have fueled advances in the fight against triple-negative breast cancer; and
WHEREAS, Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds. Further, compared with non-Hispanic white women, Black women are 48 percent less likely to receive guideline-adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from triple-negative breast cancer; and
WHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; and
WHEREAS, It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival; and
WHEREAS, Additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to triple-negative breast-cancer-related care, services, and medicines along the entire continuum of care; and
WHEREAS, The Legislature supports health promotion initiatives that target underserved communities disproportionately impacted by triple-negative breast cancer and that promote cultural sensitivity and workforce diversity policies in health care provider training and guarantee timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) Guidelines; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States; and
WHEREAS, Approximately 297,790 women will be diagnosed with breast cancer and over 43,000 will die with this malignancy in 2023; and
WHEREAS, Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 20 percent of all diagnosed invasive breast cancer cases in the United States; and
WHEREAS, More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer, with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdominal area, and those with breast cancer gene 1 (BRCA1) mutations; and
WHEREAS, Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer, and
WHEREAS, People diagnosed with metastatic triple-negative breast cancer have a less-than-30-percent chance of surviving past five years; and
WHEREAS, Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer; and
WHEREAS, Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians; and
WHEREAS, Recent innovations in targeted therapies have fueled advances in the fight against triple-negative breast cancer; and
WHEREAS, Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds. Further, compared with non-Hispanic white women, Black women are 48 percent less likely to receive guideline-adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from triple-negative breast cancer; and
WHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; and
WHEREAS, It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival; and
WHEREAS, Additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to triple-negative breast-cancer-related care, services, and medicines along the entire continuum of care; and
WHEREAS, The Legislature supports health promotion initiatives that target underserved communities disproportionately impacted by triple-negative breast cancer and that promote cultural sensitivity and workforce diversity policies in health care provider training and guarantee timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) Guidelines; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States; and
WHEREAS, Approximately 297,790 women will be diagnosed with breast cancer and over 43,000 will die with this malignancy in 2023; and
WHEREAS, Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 20 percent of all diagnosed invasive breast cancer cases in the United States; and
WHEREAS, More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer, with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdominal area, and those with breast cancer gene 1 (BRCA1) mutations; and
WHEREAS, Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer, and
WHEREAS, People diagnosed with metastatic triple-negative breast cancer have a less-than-30-percent chance of surviving past five years; and
WHEREAS, Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer; and
WHEREAS, Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians; and
WHEREAS, Recent innovations in targeted therapies have fueled advances in the fight against triple-negative breast cancer; and
WHEREAS, Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds. Further, compared with non-Hispanic white women, Black women are 48 percent less likely to receive guideline-adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from triple-negative breast cancer; and
WHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; and
WHEREAS, It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival; and
WHEREAS, Additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to triple-negative breast-cancer-related care, services, and medicines along the entire continuum of care; and
WHEREAS, The Legislature supports health promotion initiatives that target underserved communities disproportionately impacted by triple-negative breast cancer and that promote cultural sensitivity and workforce diversity policies in health care provider training and guarantee timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) Guidelines; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| May 3, 2023 | Chaptered by Secretary of State - Res. Chapter 39, Statutes of 2023. |
| May 3, 2023 | Enrolled and filed with the Secretary of State at 3 p.m. |
| Apr 20, 2023 | In Assembly. Ordered to Engrossing and Enrolling. |
| Apr 20, 2023 | Adopted and to Assembly. (Ayes 36. Noes 0. Page 815.) |
| Apr 18, 2023 | Ordered to special consent calendar. |
| Apr 12, 2023 | From committee: Ordered to third reading. |
| Mar 27, 2023 | In Senate. To Com. on RLS. |
| Mar 23, 2023 | Adopted and to Senate. (Ayes 74. Noes 0. Page 890.) |
| Mar 23, 2023 | Coauthors revised. |
| Mar 16, 2023 | From committee: Be adopted. To Consent Calendar. (Ayes 11. Noes 0.) (March 16). |
| Mar 9, 2023 | Referred to Com. on RLS. |
| Mar 2, 2023 | From printer. |
| Mar 1, 2023 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 20, 2023 | Special Consent ACR28 Reyes et al. | Senate Floor |
Passed |
|
| Mar 23, 2023 | ACR 28 Reyes Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Mar 16, 2023 | Be adopted. To Consent Calendar. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | ACR 28 |
THIRD READING
Bill No: ACR 28
Author: Reyes (D), et al.
Introduced: 3/1/23
Vote: 21
ASSEMBLY FLOOR: 74-0, 3/23/23 (Consent) - See last page for vote
SUBJECT: Triple-Negative Breast Cancer Awareness Month
SOURCE: Author
DIGEST:
This resolution proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month.
ANALYSIS: This resolution makes the following legislative findings:
- Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States. Approximately 297,790 women will be diagnosed with breast cancer and nearly 43,000 will die with this malignancy in 2023.
- Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 20 percent of all diagnosed invasive breast cancer cases in the United States.
- More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdomen area, and women with breast cancer gene 1 (BRCA1) mutations.
- Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer.
- Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer.
- Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians.
- Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds.
- Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities.
- It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival.
This resolution proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 4/10/23)
None received
OPPOSITION: (Verified 4/10/23)
None received
ASSEMBLY FLOOR: 74-0, 3/23/23
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner Horvath, Bonta, Bryan, Calderon, Juan Carrillo, Connolly, Megan Dahle, Davies, Dixon, Essayli, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO VOTE RECORDED: Wendy Carrillo, Cervantes, Chen, Maienschein, Mathis, McCarty
Prepared by: Jonas Austin / SFA / (916) 651-1520
4/12/23 13:59:20
**** END ****
Date of Hearing: March 16, 2023
ASSEMBLY COMMITTEE ON RULES
James Ramos, Chair
ABPCA Bill Id:ACR 28 (
Author:Reyes) – As Introduced Ver:March 1, 2023
SUBJECT: Triple-Negative Breast Cancer Awareness Month.
SUMMARY: Proclaims the month of March 2023 as Triple-Negative Breast Cancer Awareness Month. Specifically, this resolution makes the following legislative findings:
- Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States. Approximately 297,790 women will be diagnosed with breast cancer and nearly 43,000 will die with this malignancy in 2023.
- Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 20 percent of all diagnosed invasive breast cancer cases in the United States.
- More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdomen area, and women with breast cancer gene 1 (BRCA1) mutations.
- Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer.
- Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer.
- Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians.
- Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds.
- Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities.
- It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: Michael Erke / RLS. / (916) 319-2800
Bill Author
Bill Co-Author(s):